MDxHealth SA (NASDAQ:MDXH) Short Interest Up 133.8% in February

MDxHealth SA (NASDAQ:MDXH - Get Free Report) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 31,100 shares, an increase of 133.8% from the February 13th total of 13,300 shares. Based on an average daily volume of 113,500 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the company's shares are short sold.

Hedge Funds Weigh In On MDxHealth

A number of institutional investors have recently bought and sold shares of the stock. AWM Investment Company Inc. raised its stake in MDxHealth by 11.1% in the fourth quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company's stock worth $11,189,000 after buying an additional 471,290 shares in the last quarter. Delta Investment Management LLC bought a new position in MDxHealth in the fourth quarter worth about $81,000. FAS Wealth Partners Inc. raised its stake in MDxHealth by 49.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company's stock worth $58,000 after buying an additional 8,100 shares in the last quarter. Northern Trust Corp bought a new position in MDxHealth in the fourth quarter worth about $1,033,000. Finally, Northern Right Capital Management L.P. bought a new position in MDxHealth in the fourth quarter worth about $246,000.

MDxHealth Stock Performance

MDxHealth stock opened at $1.50 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. The firm has a 50-day moving average of $1.89 and a 200-day moving average of $2.10. The firm has a market cap of $70.93 million, a P/E ratio of -0.99 and a beta of 1.37. MDxHealth has a 1-year low of $1.35 and a 1-year high of $3.50.

Remove Ads

MDxHealth (NASDAQ:MDXH - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.07. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The company had revenue of $24.74 million during the quarter, compared to analyst estimates of $22.67 million. Sell-side analysts expect that MDxHealth will post -1.15 EPS for the current year.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.